ArticleJournal of ginseng research2026
Therapeutic potential of panax ginseng-derived nanovesicles in osteoporosis through enhanced osteoblast.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis is a skeletal disorder caused by an imbalance between bone resorption and formation, which leads to reduced bone density and increased fracture risk. Plant-derived nanovesicles have emerged as safe, biocompatible biomaterials with therapeutic potential for bone regeneration. Methods: In this work, the biological effects of Results: Treatment with PNVs (0-10 μg/mL) for 3 or 7 days markedly promoted osteoblastic maturation and matrix mineral deposition, as confirmed by Alizarin-red and Von Kossa staining. In addition, PNVs exposure upregulated key osteogenic genes, including Runx2, ALP, and OPN, while activating major signaling cascades such as BMP2/4 and phosphorylated p38, implying their involvement in osteogenic regulation. Moreover, in an ovariectomized (OVX) mouse model, oral administration of PNVs improved bone microarchitecture by stimulating osteoblast-driven bone regeneration and attenuating osteoclast-mediated bone degradation. Conclusions: Collectively, our findings indicate that PNVs promote osteoblast differentiation and bone matrix formation, thereby enhancing mineralization and demonstrating their potential as a natural nanotherapeutic approach for osteoporosis prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.